Advertisement

Topics

Graft Versus Host Disease GVHD Epidemiology Insights2023 EU5 [Updated: 31052017] Prices from USD $1488

12:48 EDT 21 Jun 2017 | BioPortfolio Reports

DelveInsight's Graft versus Host Disease GVHD Epidemiology Insights, 2023EU5 report provides an overview of the disease and global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic stem cell transplantations HSCTs and Graft Versus Host Disease GVHD based upon the subtypes of GVHD along with the type of donor involved in the HSCTs, for the forecast period 20132023.
GVHD is one of the severe complications associated with Hematopoietic stem cell transplantations HSCTs. DelveInsight forecasts predict an ongoing increase in HSCTs in the near future which shall lead to subsequent increase in the patient population of GVHD. According to DelveInsight's estimates, the total number of diagnosed incident cases of Hematopoietic Stem Cell Transplants HSCTs shall increase at a Compound Annual Growth Rate CAGR of 2.71% from 20132023 and reach up to 30,328 cases in the year 2023.
The incident rate of GVHD in unrelated donor URD is much higher in comparison to the sibling donors SD, irrespective of the subtypes i.e., acute GVHD aGVHD or chronic GVHD cGVHD. As per DelveInsight forecasts, the diagnosed incidence cases of aGVHD in sibling donors and aGVHD in unrelated donors, shall increase at a CAGR of 3.96% and 4.05%, respectively, from 20132023. In case of cGVHD, the number of diagnosed incident population cGVHD in sibling donors and cGVHD in unrelated donors is expected to accentuate at a CAGR of 4.05% and 4.04%, respectively, by the end of the year 2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse Forecast model analysis by Publisher team of industry experts.
Scope
Report covers the disease overview including pathophysiology, symptoms, diagnosis and disease management.
It focuses on the risk factors and the historical trends of the diagnosed incident cases of allogeneic Hematopoietic Stem Cell Transplants HSCTs which also includes the cases of first transplants along with the total transplants
The Report also covers the detailed historical and forecasted number of diagnosed incident cases of acute GVHD and chronic GVHD, segmented by the type of donors Sibling donors and unrelated donors for the EU5 countriesGermany, France, Italy, Spain and United Kingdom from 20132023.

Original Article: Graft Versus Host Disease GVHD Epidemiology Insights2023 EU5 [Updated: 31052017] Prices from USD $1488

NEXT ARTICLE

More From BioPortfolio on "Graft Versus Host Disease GVHD Epidemiology Insights2023 EU5 [Updated: 31052017] Prices from USD $1488"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...